机构：[1]Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.[2]The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.[3]Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.[4]Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada.[5]Department of Computer Science, University of Toronto, Toronto, ON, Canada.[6]Ontario Institute for Cancer Research, Toronto, ON, Canada.[7]Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.[8]Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.[9]The Cardiac Development and Early Intervention Unit, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, China.[10]Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.[11]Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.[12]Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.[13]Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada.
CIHR Foundation Grants (FDN 148430), CIHR Project Grant (PJT 165986), NSERC (489073), Canada Research Chair, New Investigator salary award (201512MSH360794-228629), Helen M Cooke professorship from Princess Margaret Cancer Foundation, and Ontario Institute for Cancer
Research (OICR) with funds from the province of Ontario to D.D.D.C.,
CIHR (FDN154328) to C.H.A., NSERC (RGPIN-2019-07041) to M.D.W. and
D.J.S., NSERC PGS D to D.J.S., and National Natural Science Foundation
of China (No. 32400487) to S.F. The Structural Genomics Consortium
(SGC) is a registered charity (no: 1097737) that receives funds from Bayer
AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome
Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/
McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking
[EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and
US), Pfizer and Takeda.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|1 区综合性期刊
小类|1 区综合性期刊
最新[2023]版：
大类|1 区综合性期刊
小类|1 区综合性期刊
第一作者：
第一作者机构：[1]Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.[2]The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.[2]The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.[8]Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
推荐引用方式(GB/T 7714)：
Feng Shengrui,Marhon Sajid A,Sokolowski Dustin J,et al.Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways[J].Nature Communications.2024,15(1):9321.doi:10.1038/s41467-024-53515-8.
APA：
Feng Shengrui,Marhon Sajid A,Sokolowski Dustin J,D'Costa Alister,Soares Fraser...&De Carvalho Daniel D.(2024).Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways.Nature Communications,15,(1)
MLA：
Feng Shengrui,et al."Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways".Nature Communications 15..1(2024):9321
综合性期刊